A/Prof Gopal Iyer
Dr Daniel Tan
Dr Hong Sheng QUAH
Dr Darren TOH
Dr Yvonne TENG
Fui Teen CHONG
Dorival Mendes RODRIGUES Jr
Hui Sun LEONG
Xue Lin KWANG
The Cancer Therapeutics Research Laboratory is led by Dr. Daniel Tan (medicaloncologist) and Assoc. Prof. Gopal Iyer (head and neck surgeon), both nationally funded clinician-scientists. The primary objective is to drive advances in cancer therapeutics through a translational, three-pronged strategy:
a. Multi-dimensional interrogation of samples obtained at point-of-careb. Establishing representative models to study therapeutic response and biomarkerdiscoveryc. Application of novel agents and/or combinations in the setting of co-clinical trials
a. Interrogating Tumour SamplesSamples: To study tumour heterogeneity and cancer evolution—two highlydynamic processes—and as a way to better understand exceptional therapeuticresponse, samples are acquired at the point of clinical care from resected surgicalsamples in spatially discrete regions or serial tissue and liquid biopsies.
Multi-dimensional profiling and single-cell analysis: Routine profiling includestargeted gene panels, whole-exome, whole-genome and RNA-seq. Single-cellRNAseq can further answer questions pertaining to how heterogeneity contributesto drug response and metastasis.
Immunophenotyping: The role of the immune therapy is now firmly establishedin lung and head and neck cancers. We intend to apply deep profiling strategiesto understand the immune repertoire for the identification of specific immunephenotypes and exhausted populations that have the capacity for reactivation.
b. Preclinical Disease ModellingWe have optimised protocols to establish patient-derived 2D and 3D cultures fromhead and neck squamous cell carcinoma and lung cancer. These models are tosupport projects that are ex vivo representatives of clinical scenarios (exceptionalresponders, screens, co-clinical trials, among others).
c. Translational TherapeuticsNovel therapies: Our laboratory closely interfaces with the Experimental CancerTherapeutics Unit (Phase I unit) in interrogating bio-specimens to enable the discoveryof next-generation biomarkers and explore new combinatorial approaches.
Exploiting combinatorial approaches: We are also exploring combinations thatcan be used to limit the evolution of resistance or maintain a stem-like phenotype.These insights can be applied to the clinic through innovative, adaptive clinicaltrials as well as neoadjuvant or window-of-opportunity regimens. Selected publications:
Subscribe to our mailing list to get the updates to your email inbox...
11 Hospital Drive, Singapore 169610 +65 6436 8000